China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

[XPeng Inc. (XPEV US, BUY, TP US$13.7) Target Price Change]: Buy on More Visibility of Future Growth

[Blue Lotus EV Sector Update]: All Solid-State Battery Unlikely to Disrupt EV Market

[XPeng(XPEV US, BUY, TP US$24.3)TP Change]: Potential of Tech Licensing and EV Sales Lifts Valuation

[XPeng (XPEV US) Earnings Review]: Facing Price War and Fiercer Competition in 2023

[XPeng (XPEV US, BUY, TP US$11.5) Rating Change]: G6 Is a Superb Answer to Tesla Model Y…UG to BUY

Xpeng Inc. (XPEV US) – 4Q22E Net Loss to Narrow; Sales as Key to FY23

China/Asia TMT

Shawn Yang

Equity Bottom-Up

<ul>
<li>XPeng reported soft 1Q23 results, with topline of RMB 4.03bn, missing cons by (4.4%); GPM of 1.7% missing cons. and our est. by (4.5ppt)/(4.8ppt. </li>
<li>The 2Q23 guidance implies a QoQ recovery of 15.2%-20.7%, thanks to increasing order intake of the all-new P7i and recent channel transformation. </li>
<li>We maintain BUY. We cut TP to US$ 10 due to pressure amid intensified competition.</li>
</ul>


XPeng reported soft 1Q23 results, with topline of RMB 4.03bn, missing cons by (4.4%); GPM of 1.7% missing cons. and our est. by (4.5ppt)/(4.8ppt. 
The 2Q23 guidance implies a QoQ recovery of 15.2%-20.7%, thanks to increasing order intake of the all-new P7i and recent channel transformation. 
We maintain BUY. We cut TP to US$ 10 due to pressure amid intensified competition.


[XPeng Inc. (XPEV US, 매수, 목표주가 US$10) 목표주가 변동]: 2Q23부터 회복세 시작, 매수